Reaction Biology Corporation is an industry leader and innovator specializing in assay services and protein production for early-stage drug discovery. Founded in 2001, Reaction Biology offers a wide range of services, including robust biochemical, biophysical, electrophysiological and cell assay technologies for high throughput screening (HTS) and selectivity compound profiling. RBC's target covering is wide, covering more than 1000 different targets, heavily focused on kinase and epigenetic targets. We also offer relevant HTS assay reagents, including highly purified and characterized epigenetic proteins. On average, several million HTS and profiling reactions are performed per year. Over 750 companies worldwide, including pharmaceutical, biotech, academic, and nonprofit laboratories, utilize our biochemical and cellular assay services and purchase epigenetic proteins.